Buflomedil hydrochloride 是一种血管扩张剂，可用于外周动脉疾病引发的一系列症状。

Buflomedil hydrochloride, a vasodilator, is used in therapy of claudication or the symptoms of the peripheral arterial disease.

Buflomedil enhances intracellular cAMP levels in human keratinocytes, either secondary to adenyl-cyclase stimulation (BC) or phosphodiesterase inhibition (PTX). Buflomedil diminishes release of TPA-induced TNF-alpha and IL-8 in keratinocytes; in the case of IL-8, this inhibition may occur to transcriptional level. At the micromolar level, Buflomedil notably inhibits epinephrine-induced aggregation. Buflomedil leads to a weak inhibition of collagen- and ADP-induced aggregation. Buflomedil inhibits grainy secretion and the interaction of fibrinogen with its receptor on platelet. the capillary perfusion is improved by Buflomedil hypochloride in such related situations, evoking a possible effect upon neutrophils. Buflomedil Completely inhibits adhesion of histamine related neutrophil (flow system) and partially inhibits adhesion after IL-1-4 hours (flow and stable systems). Buflomedil lowers the hypoxia-induced neutrophil adhesion and expression of P-selectin at the surface of endothelial cells.

35543-24-9

C17H26ClNO4

343.85

盐酸丁咯地尔;丁咯地尔盐酸盐;Fonzylane;Buflomedil HCl;Loftyl

H2O:63 mg/mL (183.2 mM)
Ethanol:7 mg/mL (20.35 mM)
DMSO:29 mg/mL (84.3 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years